{
    "root": "0823087f-bdff-4578-b259-cc6062dfc991",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Divalproex sodium",
    "value": "20250328",
    "ingredients": [
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER (2:1; 750000 MW)",
            "code": "P2OM2Q86BI",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_82327"
        },
        {
            "name": "ETHYLCELLULOSE (7 MPA.S)",
            "code": "H3UP11403C",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11228"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "HYPROMELLOSE 2208 (100000 MPA.S)",
            "code": "VM7F0B23ZI",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "indications": {
        "text": "divalproex sodium extended-release tablets indicated : \u2022 acute treatment manic mixed episodes associated bipolar disorder , without psychotic features ( 1.1 ) \u2022 monotherapy adjunctive therapy complex partial seizures simple complex absence seizures ; adjunctive therapy patients multiple seizure types include absence seizures ( 1.2 ) \u2022 prophylaxis migraine headaches ( 1.3 )",
        "doid_entities": [
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            },
            {
                "text": "migraine (DOID:6364)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6364"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 divalproex sodium extended-release tablets intended once-a-day oral . divalproex sodium extended-release tablets swallowed whole crushed chewed ( 2.1 , 2.2 ) . \u2022 mania : initial dose 25 mg/kg/day , increasing rapidly possible achieve therapeutic response desired plasma level ( 2.1 ) . maximum recommended 60 mg/kg/day ( 2.1 , 2.2 ) . \u2022 complex partial seizures : start 10 15 mg/kg/day , increasing 1 week intervals 5 10 mg/kg/day achieve optimal response ; response satisfactory , check valproate plasma level ; full prescribing information conversion monotherapy ( 2.2 ) . maximum recommended 60 mg/kg/day ( 2.1 , 2.2 ) . \u2022 absence seizures : start 15 mg/kg/day , increasing 1 week intervals 5 10 mg/kg/day seizure control limiting side effects ( 2.2 ) . maximum recommended 60 mg/kg/day ( 2.1 , 2.2 ) . \u2022 migraine : recommended starting dose 500 mg/day 1 week , thereafter increasing 1,000 mg/day ( 2.3 ) .",
        "doid_entities": [
            {
                "text": "migraine (DOID:6364)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6364"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "divalproex sodium extended-release tablets usp , 500 mg available grey colored , oval shaped , film coated tablets , imprinted `` l089 `` one side plain side . divalproex sodium extended-release tablet contains divalproex sodium equivalent 500 mg valproic acid following packaging sizes : bottle 30 ( ndc 68788-8358-3 ) bottle 60 ( ndc 68788-8358-6 ) bottle 90 ( ndc 68788-8358-9 ) recommended storage store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) . [ usp controlled room temperature ] . dispense usp tight , light-resistant container .",
    "adverseReactions": "\u2022 hepatic disease significant hepatic dysfunction ( 4 , 5.1 ) \u2022 known mitochondrial disorders caused mutations mitochondrial dna polymerase \u03b3 ( polg ) ( 4 , 5.1 ) \u2022 suspected polg-related disorder children two years age ( 4 , 5.1 ) \u2022 known hypersensitivity ( 4 , 5.12 ) \u2022 urea cycle disorders ( 4 , 5.6 ) \u2022 prophylaxis migraine headaches : pregnant women , women childbearing potential using effective contraception ( 4 , 8.1 )",
    "indications_original": "Divalproex sodium extended-release tablets are indicated for: \u2022 Acute treatment of manic or mixed episodes associated with      bipolar disorder, with or without psychotic features ( 1.1 ) \u2022 Monotherapy and adjunctive therapy of complex partial      seizures and simple and complex absence seizures; adjunctive therapy in patients      with multiple seizure types that include absence seizures ( 1.2) \u2022 Prophylaxis of migraine headaches ( 1.3)",
    "contraindications_original": "\u2022 Divalproex sodium extended-release tablets are intended      for once-a-day oral administration. Divalproex sodium extended-release      tablets should be swallowed whole and should not be crushed or chewed      ( 2.1 , 2.2 ). \u2022 Mania: Initial dose is 25 mg/kg/day, increasing as rapidly      as possible to achieve therapeutic response or desired plasma level (2.1).      The maximum recommended dosage is 60 mg/kg/day      ( 2.1 , 2.2 ). \u2022 Complex Partial Seizures: Start at 10 to 15 mg/kg/day,      increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal      clinical response; if response is not satisfactory, check valproate plasma      level; see full prescribing information for conversion to monotherapy      ( 2.2 ). The maximum recommended dosage is 60      mg/kg/day ( 2.1 , 2.2 ). \u2022 Absence Seizures: Start at 15 mg/kg/day, increasing at 1      week intervals by 5 to 10 mg/kg/day until seizure control or limiting side      effects (2.2). The maximum recommended dosage is 60 mg/kg/day      ( 2.1 , 2.2 ). \u2022 Migraine: The recommended starting dose is 500 mg/day for      1 week, thereafter increasing to 1,000 mg/day      ( 2.3 ).",
    "warningsAndPrecautions_original": "Divalproex sodium extended-release tablets USP, 500 mg are available as grey colored, oval shaped, film coated tablets, imprinted \"L089\" on one side and plain on the other side. Each divalproex sodium extended-release tablet contains divalproex sodium equivalent to 500 mg of valproic acid in the following packaging sizes:\n                  Bottle of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (NDC 68788-8358-3)\n                  Bottle of 60\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (NDC 68788-8358-6)\n                  Bottle of 90\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (NDC 68788-8358-9)\n                  \n                     \n                        Recommended Storage\n                     \n                  \n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). [See USP Controlled Room Temperature]. Dispense in a USP tight, light-resistant container.",
    "adverseReactions_original": "\u2022 Hepatic disease or significant      hepatic dysfunction ( 4 , 5.1 ) \u2022 Known mitochondrial disorders      caused by mutations in mitochondrial DNA polymerase \u03b3 (POLG)      ( 4 , 5.1 ) \u2022 Suspected POLG-related      disorder in children under two years of age ( 4 , 5.1 ) \u2022 Known hypersensitivity to the      drug ( 4 , 5.12 ) \u2022 Urea cycle disorders      ( 4 , 5.6) \u2022 Prophylaxis of migraine      headaches: Pregnant women, women of childbearing potential not using      effective contraception ( 4 , 8.1 )",
    "drug": [
        {
            "name": "Divalproex sodium"
        }
    ]
}